<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181386</url>
  </required_header>
  <id_info>
    <org_study_id>Odonto-NOAC</org_study_id>
    <nct_id>NCT03181386</nct_id>
  </id_info>
  <brief_title>Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants</brief_title>
  <official_title>Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of a protocol which does not suspend the
      new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions
      in patients with non-valvular atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample will be divided into three groups according to the pharmacokinetics of the oral
      anticoagulant: rivaroxaban 1x/day (group 1); dabigatran and apixabana 2x/day (group 2) and
      warfarin (control group). Extraction of one to three teeth will be scheduled, in the valley
      of the new oral anticoagulants' concentration, considered the period of smallest haemorrhagic
      risk without suspension. In group 1 the surgery will be scheduled 14 hours after the last
      intake, in group 2 the surgery will be scheduled 8 hours after the last intake, while the
      control group will undergo the procedure with INR values between 2.0 and 3,0. Hemostatic
      measures with tranexamic acid paste intra alveolar, suture and biological glue GRF® (gelatin,
      resorcinol and formaldehyde) and post operative care will be associated. The patients will be
      contacted after the procedure to inform the presence or absence of late bleeding. The patient
      should return 24 hours later to evaluate the surgical site. This protocol is based on
      Guidelines and scientific articles, pharmacokinetics and clinical experience of the authors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A bleeding event (incidence of postoperative bleeding events)</measure>
    <time_frame>7 days</time_frame>
    <description>To evaluate the safety of a protocol regarding the risks of bleeding after dental extractions performed in patients with non-valvular atrial fibrillation in continuous use of the new oral anticoagulants, we compared the incidence of postoperative bleeding events after dental extractions between patients in use of new oral anticoagulants and those treated of warfarin without withdrawal of oral anticoagulant therapy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Periodontal Disease</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran and Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran and Apixaban</intervention_name>
    <description>Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.</description>
    <arm_group_label>Dabigatran and Apixaban</arm_group_label>
    <other_name>Pradaxa and Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Marevan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Selection of patients: Both genders, aged over 18 years, regardless of ethnicity,
             marital status, nationality, naturalness or profession, with non-valvular atrial
             fibrillation using dabigatran or rivaroxaban or apixaban or warfarin, under medical
             outpatient treatment or during the hospitalization period.

          -  Dentistry: Patients with indications of exodontia of one to three permanent adjacent
             teeth erupted in the maxilla or mandible due to extensive dental caries or periodontal
             disease.

        Exclusion Criteria:

          -  Clinical: Patients on concomitant use of antiplatelet agents or heparin, pregnant and
             lactating patients, with coagulation disorders, severe chronic renal insufficiency
             (CrCl &lt;30), severe hepatopathies and proven to be allergic to lidocaine and / or
             epinephrine.

          -  Dentistry: Odontophobic, edentulous, or healthy teeth; Deciduous teeth and Included
             teeth.

          -  Regarding the time of medication intake: Regarding the time of medication intake
             Patients taking rivaroxaban who routinely take the medication between 5:00 a.m. to
             4:00 p.m. (unworkable schedule for surgery) that do not accept a change in the intake
             schedule suggested by the attending physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise T Hachul, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Itamara LI Neves, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elaine M Higashi, S</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo S Neves, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco CC Darrieux, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricio I Scanavacca, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Itamara LI Neves, PhD</last_name>
    <phone>55-11-26615229</phone>
    <email>itamara.neves@incor.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine M Higashi, S</last_name>
    <phone>55-11-981098642</phone>
    <email>elaine_mh@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine M Higashi, S</last_name>
      <phone>55-1126614142</phone>
      <email>elaine_mh@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Itamara LI Neves, PhD</last_name>
      <phone>55-1126614142</phone>
      <email>itamara.neves@incor.usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </reference>
  <reference>
    <citation>Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: biology and dental implications. Med Oral Patol Oral Cir Bucal. 2013 May 1;18(3):e461-72. Review.</citation>
    <PMID>23524440</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350. Erratum in: Europace. 2011 Jul;13(7):1058. Dosage error in article text.</citation>
    <PMID>20876603</PMID>
  </reference>
  <reference>
    <citation>Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864-72. doi: 10.1093/eurheartj/ehu046. Epub 2014 Feb 20.</citation>
    <PMID>24561548</PMID>
  </reference>
  <reference>
    <citation>Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):575-80. doi: 10.1016/j.oooo.2011.10.006. Epub 2012 Mar 3. Review.</citation>
    <PMID>22668618</PMID>
  </reference>
  <reference>
    <citation>Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):431-41. doi: 10.1016/j.oooo.2011.10.005.</citation>
    <PMID>22668425</PMID>
  </reference>
  <reference>
    <citation>Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis. 2016 Jan;22(1):23-32. doi: 10.1111/odi.12371. Epub 2015 Nov 16. Review.</citation>
    <PMID>26386350</PMID>
  </reference>
  <reference>
    <citation>van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.</citation>
    <PMID>20352166</PMID>
  </reference>
  <reference>
    <citation>Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e191-5. doi: 10.1016/j.oooo.2013.05.001. Epub 2013 Jul 10.</citation>
    <PMID>23850368</PMID>
  </reference>
  <reference>
    <citation>Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013;79:d74. Review.</citation>
    <PMID>23920075</PMID>
  </reference>
  <reference>
    <citation>Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26. Review.</citation>
    <PMID>23014816</PMID>
  </reference>
  <reference>
    <citation>Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009 May;37(5):1056-64. doi: 10.1124/dmd.108.025569. Epub 2009 Feb 5.</citation>
    <PMID>19196845</PMID>
  </reference>
  <reference>
    <citation>Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.</citation>
    <PMID>21830957</PMID>
  </reference>
  <reference>
    <citation>Haas S, Bode C, Norrving B, Turpie AG. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag. 2014 Mar 10;10:101-14. doi: 10.2147/VHRM.S55246. eCollection 2014. Review.</citation>
    <PMID>24648742</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Friedman RJ, Kurth A, Clemens A, Noack H, Eriksson BI, Caprini JA. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost. 2012 Jul;108(1):183-90. doi: 10.1160/TH11-08-0589. Epub 2012 May 3.</citation>
    <PMID>22552763</PMID>
  </reference>
  <reference>
    <citation>Härtter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol. 2013 Mar;69(3):327-39. doi: 10.1007/s00228-012-1304-8. Epub 2012 Jul 11.</citation>
    <PMID>22782539</PMID>
  </reference>
  <reference>
    <citation>Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol. 2006 Sep;46(9):981-90.</citation>
    <PMID>16920892</PMID>
  </reference>
  <reference>
    <citation>Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res. 2012 Aug;130(2):147-51. doi: 10.1016/j.thromres.2011.12.005. Epub 2012 Jan 5.</citation>
    <PMID>22225858</PMID>
  </reference>
  <reference>
    <citation>Scott A, Gibson J, Crighton A. The management of dental patients taking new generation oral anticoagulants. Prim Dent J. 2014 Nov;3(4):54-8. doi: 10.1308/205016814813877289.</citation>
    <PMID>25668377</PMID>
  </reference>
  <reference>
    <citation>Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083.</citation>
    <PMID>23625942</PMID>
  </reference>
  <reference>
    <citation>Hong C, Napenas JJ, Brennan M, Furney S, Lockhart P. Risk of postoperative bleeding after dental procedures in patients on warfarin: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct;114(4):464-8. doi: 10.1016/j.oooo.2012.04.017.</citation>
    <PMID>22986241</PMID>
  </reference>
  <reference>
    <citation>Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011 Dec;104(12):669-76. doi: 10.1016/j.acvd.2011.09.001. Epub 2011 Oct 29.</citation>
    <PMID>22152517</PMID>
  </reference>
  <reference>
    <citation>Clemm R, Neukam FW, Rusche B, Bauersachs A, Musazada S, Schmitt CM. Management of anticoagulated patients in implant therapy: a clinical comparative study. Clin Oral Implants Res. 2016 Oct;27(10):1274-1282. doi: 10.1111/clr.12732. Epub 2015 Nov 23.</citation>
    <PMID>26592859</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Itamara Lucia Itagiba Neves</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Dabigatran</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Tooth Extraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After thesis defense, the IPD will be available on the Portal Digital Library of Theses and Dissertations of the University of São Paulo (http://www.teses.usp.br/index.php?option=com_jumi&amp;fileid=12&amp;Itemid=77&amp;lang=ptbr), in a PDF file.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

